These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

576 related articles for article (PubMed ID: 7870068)

  • 21. CMV antigenemia (the lower matrix protein PP65), a marker for the guidance of antiviral therapy in cytomegalovirus disease after orthotopic heart transplantation.
    Iberer F; Tscheliessnigg KH; Halwachs G; Auer T; Wasler A; Petutschnigg B; Müller H; Freigassner M; Allmayr T; Hipmair G
    Wien Klin Wochenschr; 1995; 107(23):718-22. PubMed ID: 8560893
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Analysis of a quantitative PCR assay for CMV infection in liver transplant recipients: an intent to find the optimal cut-off value.
    Martín-Dávila P; Fortún J; Gutiérrez C; Martí-Belda P; Candelas A; Honrubia A; Barcena R; Martínez A; Puente A; de Vicente E; Moreno S
    J Clin Virol; 2005 Jun; 33(2):138-44. PubMed ID: 15911429
    [TBL] [Abstract][Full Text] [Related]  

  • 23. CMV monitoring after peripheral blood stem cell and bone marrow transplantation by pp65 antigen and quantitative PCR.
    Schulenburg A; Watkins-Riedel T; Greinix HT; Rabitsch W; Loidolt H; Keil F; Mitterbauer M; Kalhs P
    Bone Marrow Transplant; 2001 Oct; 28(8):765-8. PubMed ID: 11781628
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Comparison of polymerase chain reaction from plasma and buffy coat with antigen detection and occurrence of immunoglobulin M for the demonstration of cytomegalovirus infection after liver transplantation.
    Schmidt CA; Oettle H; Peng R; Neuhaus P; Blumhardt G; Lohmann R; Wilborn F; Osthoff K; Oertel J; Timm H
    Transplantation; 1995 Apr; 59(8):1133-8. PubMed ID: 7732559
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Effectiveness of preemptive therapy with ganciclovir in recipients of renal transplants at high risk (R-/D+) for the development of cytomegalovirus disease].
    Aranda-Verástegui F; Alberú J; Soto-Ramírez LE; González-Aguirre H; Muñoz Trejo T; Mancilla E; Díliz H; Correa-Rotter R; Sierra-Madero J
    Rev Invest Clin; 2002; 54(3):198-203. PubMed ID: 12183888
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Early diagnosis and monitoring of active HCMV infection in children with systemic lupus erythematosus.
    Zhang C; Shen K; Jiang Z; He X
    Chin Med J (Engl); 2001 Dec; 114(12):1309-12. PubMed ID: 11793860
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A prospective study comparing quantitative Cytomegalovirus (CMV) polymerase chain reaction in plasma and pp65 antigenemia assay in monitoring patients after allogeneic stem cell transplantation.
    Gentile G; Picardi A; Capobianchi A; Spagnoli A; Cudillo L; Dentamaro T; Tendas A; Cupelli L; Ciotti M; Volpi A; Amadori S; Martino P; de Fabritiis P
    BMC Infect Dis; 2006 Nov; 6():167. PubMed ID: 17118205
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Relation between pp65 antigenemia, RT-PCR and viruria for cytomegalovirus detection in kidney transplant recipients.
    Solà R; Rabella N; Guirado LL; Díaz JM; Facundo C; García R
    Transplant Proc; 2005 Nov; 37(9):3768-9. PubMed ID: 16386533
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Onset and duration of cytomegalovirus immediate early 1 mRNA expression in the blood of renal transplant recipients.
    Goossens VJ; Christiaans MH; Blok MJ; Terporten PH; Sillekens P; Lukacsi A; Van Hooff JP; Bruggeman CA
    J Med Virol; 2004 Jan; 72(1):94-101. PubMed ID: 14635016
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [The prognostic value of cytomegalovirus antigenemia and viremia for the development of cytomegalovirus disease and the survival of AIDS patients].
    Cartón JA; Maradona JA; de Oña M; Asensi V; Melón S; García-Alcalde ML; Rodríguez-Junquera M; Moreno-Torrico A; de Zárraga M
    Med Clin (Barc); 1999 Sep; 113(6):205-9. PubMed ID: 10472608
    [TBL] [Abstract][Full Text] [Related]  

  • 31. CMV PCR in leucocytes as an early marker for the development of CMV disease in AIDS patients.
    Quarner H; Grützmeier S; Lewensohn-Fuchs I; Hejdeman B; Sandström E; Ehrnst A
    Scand J Infect Dis Suppl; 1995; 99():94-5. PubMed ID: 8668950
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Expression dynamics of human cytomegalovirus immune evasion genes US3, US6, and US11 in the blood of lung transplant recipients.
    Greijer AE; Verschuuren EA; Dekkers CA; Adriaanse HM; van der Bij W; The TH; Middeldorp JM
    J Infect Dis; 2001 Aug; 184(3):247-55. PubMed ID: 11443549
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Early diagnosis of cytomegalovirus infection and disease in patients following kidney transplantation].
    Cathomas G; Tamm M; Bock A; Gudat F; Thiel G; Reusser P
    Schweiz Med Wochenschr; 1994 Nov; 124(45):2042-5. PubMed ID: 7973539
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [pp65 antigenemia in evaluation of cytomegalovirus infection after kidney transplantation].
    Orlić P; Dvornik S; Husnjak SC; Aralica M; Orlić L; Zivcić-Cosić S; Sladoje-Martinović B; Fućak M
    Acta Med Croatica; 2003; 57(1):49-52. PubMed ID: 12876863
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Quantitative PCR in the diagnosis of CMV infection and in the monitoring of viral load during the antiviral treatment in renal transplant patients.
    Piiparinen H; Helanterä I; Lappalainen M; Suni J; Koskinen P; Grönhagen-Riska C; Lautenschlager I
    J Med Virol; 2005 Jul; 76(3):367-72. PubMed ID: 15902704
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Virological diagnosis of cytomegalovirus in renal transplantation: comparison of three diagnostic methods: DNA in plasma by PCR, PP65 leukocytic antigenemia, and viremia.
    Eckart P; Brouard J; Legoff C; Freymuth F; Duhamel JF; Ryckelynck JP; Hurault De Ligny B
    Transplant Proc; 1996 Oct; 28(5):2806-7. PubMed ID: 8908069
    [No Abstract]   [Full Text] [Related]  

  • 37. A prospective study comparing cytomegalovirus antigenemia, DNAemia and RNAemia tests in guiding pre-emptive therapy in thoracic organ transplant recipients.
    Lehto JT; Lemström K; Halme M; Lappalainen M; Lommi J; Sipponen J; Harjula A; Tukiainen P; Koskinen PK
    Transpl Int; 2005 Dec; 18(12):1318-27. PubMed ID: 16297050
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Analytic validation of a quantitative real-time PCR assay to measure CMV viral load in whole blood.
    Thorne LB; Civalier C; Booker J; Fan H; Gulley ML
    Diagn Mol Pathol; 2007 Jun; 16(2):73-80. PubMed ID: 17525675
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Comparison of the Murex Hybrid Capture CMV DNA (v2.0) assay and the pp65 CMV antigenemia test for the detection and quantitation of CMV in blood samples from immunocompromised patients.
    Schirm J; Kooistra A; van Son WJ; van der Bij W; Verschuuren E; Sprenger HG; Limburg PC; The TH
    J Clin Virol; 1999 Dec; 14(3):153-65. PubMed ID: 10614852
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Comparison of two commercially available pp65 antigenemia tests and COBAS Amplicor CMV Monitor for early detection and quantification of episodes of human CMV-viremia in transplant recipients.
    May G; Kuhn JE; Eing BR
    Intervirology; 2006; 49(5):261-5. PubMed ID: 16714854
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 29.